MOMAT RINO ADVANCE SPRAY NASAL

$24.50
No tax

MOMAT RINO ADVANCE SPRAY NASAL 140/50 ΜG/DOSE 150 DOSES

Quantity

 

Security policy (edit with Customer reassurance module)

 

Delivery policy (edit with Customer reassurance module)

 

Return policy (edit with Customer reassurance module)

Latin name

Momate Rhino Advance

Packaging

In the package 150 doses.

Mechanism of action

Azelastine, a phthalazinone derivative, is a long-acting antiallergic agent. Azelastine is a selective H i-histamine blocker, has anti-histamine, antiallergic and membrane stabilizing effect, reduces capillary permeability and exudation, stabilizes the membranes of mast cells and prevents the release of biologically active substances (histamine, serotonin, heart factors, factors, and humans, factors, and humans, factors, and humans, factors, release factors, prevent factors from releasing from them (histamine, serotonin, lymphocytes), prevents factors from releasing of biologically active substances (histamine, serotonin, heart factors, factors, factors, factors, and humans, factors, and humans, factors, and humans, factors, release factors, histomine, serotonin, lymphocytes, etc. others), causing bronchospasm and contributing to the development of early and late stages of allergic reactions and inflammation.

mometasone is a synthetic glucocorticosteroid (GCS) for topical use. It has anti-inflammatory and anti-allergic effects when used in doses that do not cause systemic effects. Slows down the release of inflammatory mediators. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, which leads to a decrease in the release of arachidonic acid and, respectively. inhibition of the synthesis of products of the metabolism of arachidonic acid - cyclic endoperoxides, prostaglandins.It warns the regional accumulation of neutrophils, which reduces inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, leads to a decrease in the processes of infiltration and granulation. Reduces inflammation by reducing the formation of chemotaxis substance (the effect on late allergy reactions), inhibits the development of an immediate type of allergic reaction (due to inhibition of the production of arachidonic acid metabolites and reduced release of inflammatory mediators from mast cells).

Pharmacokinetics

Azelastine hydrochloride. Bioavailability after iptnasal administration is about 40%. The maximum concentration (Cax) in the blood plasma after intranasal use is achieved in 2-3 hours. When applied intranasally at a daily dose of 0.56 mg azelastine hydrochloride, the average equilibrium concentration of azelastine hydrochloride in the plasma 2 hours after administration is 0.65 ng / ml. Doubling the total daily dose to 1.12 mg leads to a steady average plasma concentration of azelastine equal to 1.09 ng / ml. However, despite the relatively high absorption in patients, systemic exposure after intranasal administration is approximately 8 times lower than after oral administration of a daily dose of 4.4 mg azelastine hydrochloride, which is a therapeutic oral dose for the treatment of allergic rhinitis. Intranasal use in patients with allergic rhinitis causes an increase in plasma azelastine levels compared with healthy subjects. Other pharmacokinetic data have been studied with oral administration. Communication with blood proteins 80 - 90%.Metabolized in the liver by oxidation with the participation of the cytochrome P450 system with the formation of the active metabolite dezmetilazelastina. Excreted mainly by the kidneys as inactive metabolites. The elimination half-life (T1 / 2) of azelastine is about 20 hours, its active metabolite dezmetilazelastina is about 45 hours.

Mometasone furoate. With intranasal use, the systemic bioavailability of the momet-furoate zone is <1% (with a detection method sensitivity of 0.25 pg / ml). The mometasone suspension is very poorly absorbed in the gastrointestinal tract, and the small amount of mometasone suspension that can enter the gastrointestinal tract after nasal inhalation, even before excretion with urine or bile, is subjected to an active primary metabolism.

Indications

Seasonal allergic rhinitis in adults from 18 years.

Contraindications

Hypersensitivity to any of the components of the drug.

- Recent surgery or injury of the nose with damage to the mucous membrane of the nasal cavity - until the wound heals (due to the inhibitory effect of the SCS on the healing process).

Children's age up to 18 years - due to the lack of relevant data.

Carefully

Tuberculosis infection (active and latent) of the respiratory tract, untreated fungal, bacterial, systemic viral infection or Herpes simplex infection with eye damage (as an exception, the drug may be prescribed for the listed infections as directed by the doctor), the presence of an untreated infection involving the mucous process shell of the nasal cavity.

Use during pregnancy and lactation

A properly planned and buried controlled study of the drug in pregnant women has not been conducted.

Azelastine hydrochloride can cause toxicity during fetal development in mice, rats and rabbits.

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Use during pregnancy and lactation

Contraindicated.

Special notes

As with any long-term treatment, patients using Mo-mat Reno Advance nasal spray for several months or longer should periodically be examined by a physician for possible changes in the nasal mucosa, nasal septum perforation (very rarely) and the possible development of systemic side effects. effects. If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue the Momat Rino Advance nasal spray therapy and conduct special treatment. In case of development of persistent irritation of the nasopharynx, it is necessary to resolve the issue of discontinuing therapy.
Patients who switch to treatment with Momat Rino Advance nasal spray after long-term treatment with systemic glucocorticosteroids require special attention. Cancellation of systemic-acting glucocorticosteroids in such patients may lead to insufficient adrenal function, the subsequent recovery of which may take up to several months.In case of signs of adrenal insufficiency, you should resume taking systemic corticosteroids and take other necessary measures.
During the transition from treatment with glucocorticosteroids of systemic action to treatment with nasal spray Momat Rino Advance, some patients may experience initial withdrawal symptoms of systemic glucocorticosteroids (for example, pain in joints and / or muscles, feeling tired and depressed), despite a reduction in the severity of symptoms associated with lesion of the nasal mucosa; such patients need to be specifically convinced of the desirability of continuing treatment with the nasal spray Momat Rino Advance. The transition from systemic to local glucocorticosteroids can also reveal pre-existing, but masked therapy with glucocorticosteroids of systemic action, allergic diseases such as allergic conjunctivitis and eczema.
When using intranasal steroids in doses higher than recommended, or in sensitive patients at recommended doses, systemic effects of glucocorticosteroids and suppression of the adrenal glands can develop. When such changes occur, the use of the Momat Rino Advance nasal spray should be gradually discontinued, in accordance with the procedures taken to stop taking oral glucocorticosteroids.
Patients who are treated with glucocorticosteroidshave potentially reduced immune reactivity and should be warned about the increased risk of infection in case of contact with patients with certain infectious diseases (eg, chicken pox, measles), and the need for medical advice if such contact has occurred.
If signs of severe bacterial infection appear (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical consultation is required. Glucocorticosteroids for nasal and inhalation use can cause the development of glaucoma and / or cataracts. Therefore, it should be carefully monitored for patients with vision changes, as well as for patients who have previously had elevated intraocular pressure, glaucoma and / or cataracts.
Influence on ability to drive vehicles and engage in other activities
In rare cases, fatigue, fatigue, dizziness and weakness, which may be the result of the disease itself, may develop with the use of Momat Rino Advance nasal spray. In such cases, you should avoid driving and working with complex mechanisms.

Composition

1 spray dose contains:

Active ingredients:

azelastine hydrochloride - 140 µg, mometasone furoate - 50 µg.

Excipients:

microcrystalline cellulose (Avitsel RC-591) - 0.910 mg, carmellose sodium -0.021 mg, dextrose - 3,500 mg, polysorbate-80 - 0,0175 mg, benzalkonium chloride - 0.014 mg, disodium edetate-0.035 mg, neotam - 0.0007 mg , citric acid monohydrate - 0.0105 mg, sodium citrate - 0.021 mg, purified water - up to 70 mg.

Dosage and administration

It is intranasal. Inhalation of the suspension contained in the vial is carried out using a special dispensing nozzle on the vial. On 1 dose of spray (azelastine hydrochloride - 140 µg / momstazona furoate - 50 µg) in each nostril 2 times a day, morning and evening. Duration of treatment is 2 weeks.

Side effects

The frequency of side effects is defined as follows: Very often:> 1/10; Often: <1/10> 1/100;

11frequently: 1/1000; Rarely: <1/1000> 1/10000; Very rare: <1/10000.

Nervous system disorders:

Often: headache, dysgeusia (unpleasant taste) as a result of misuse. namely, when the head is excessively deflected back during administration.

Very rarely, dizziness (may be caused by the disease itself).

Violations of the gastrointestinal tract:

Seldom: feeling of irritation of a mucous membrane of a throat, nausea.

Disturbances of the respiratory system, organs of the chest and mediastinum: Often: nasal bleeding, discomfort in the nasal cavity (burning sensation, itching), ulceration of the nasal mucosa, sneezing, pharyngitis, sinusitis, infections of the upper respiratory tract.

Immune system disorders:

Very rare: hypersensitivity, anaphylactoid reactions.

Violations of the skin and subcutaneous tissues:

Very rare: rash, pruritus, urticaria.

General disorders and disorders at the site of administration:

Very rarely: fatigue, drowsiness, weakness (may be caused by the disease itself).

With long-term use of glucocorticosteroids (GCS) in high doses, systemic side effects, including glaucoma and cataracts, may develop.

Drug interaction

Azelastine. There were no clinically significant interactions with other drugs with the intranasal use of azelastip.

Mometasone furoate. Combination therapy with loratadine was well tolerated by patients. However, no effect of the drug on the concentration of Lora-Tadin or its main metabolite in the blood plasma was noted. In these studies, mometasone furoate was not detected in the blood plasma (with a sensitivity of the method of determination of 50 pg / ml).

Overdose

At the moment, cases of overdose of the drug with inranasal application is unknown. In case of an overdose of azelastine as a result of accidental ingestion, there may be disturbances in the nervous system (drowsiness, confusion, tachycardia, hypotension). Therapy for these disorders is symptomatic. With prolonged use of glucocorticosteroids in high doses, as well as with the simultaneous use of several corticosteroids, the hypothalamic-pituitary-adrenal system may be inhibited. Due to the low systemic bioavailability of the drug is unlikelythat in case of an accidental or deliberate overdose, it will be necessary to take any measures other than observation, with possible subsequent resumption of the drug in the recommended dose.

Storage conditions

In the dark place at a temperature of 15-25 ° C (not freezing).

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiration date printed on the package.

88 Items